L'angolo del dottorino
Group II Anemias:
Ineffective Erythropoiesis
The anemias due to ineffective erythropoiesis (also referred to as group II anemias or anemias due to a qualitative defect of erythropoiesis) are a heterogeneous group of hematologic disorders characterized by impaired maturation of erythroid precursors in the bone marrow. In these conditions, although erythroid lineage proliferation is often preserved or increased, the maturation process is impaired, resulting in intramedullary death of precursors and reduced production of functional red blood cells.
The distinguishing feature of these forms is hypoproliferative anemia associated with often hypercellular bone marrow rich in morphologically abnormal erythroid precursors, often with signs of dysmaturation or pathologic iron accumulation. Unlike erythroblastopenias (group I), in which red blood cell production is reduced because of an early quantitative block, in group II anemias the defect involves maturation of erythroid precursors, resulting in overall inefficiency of red blood cell production and a reduced capacity of the bone marrow to compensate for the red blood cell deficit.
This category includes both acquired and congenital forms. Acquired forms include vitamin B12 deficiency anemia, pernicious anemia and folate deficiency anemia; congenital and dysplastic forms include sideroblastic anemia and anemia of myelodysplastic syndrome.
The anemias due to ineffective erythropoiesis can occur at any age, with clinical presentations and prognosis varying according to etiology, age at onset, degree of bone marrow inefficiency, and comorbidities. Correct distinction from other groups of anemia, understanding the pathophysiologic basis, assessing risk factors, and choosing an individualized diagnostic and therapeutic pathway are essential for effective patient management.
Etiology, pathogenesis, and pathophysiology
The causes of anemias due to ineffective erythropoiesis are numerous and can be divided into acquired forms and congenital forms, each characterized by its own pathogenic mechanisms and specific clinical patterns.
Among the acquired forms, particularly important are vitamin B12 deficiencies, pernicious anemia and folate deficiency. In particular, pernicious anemia is caused by an autoimmune mechanism involving gastric parietal cells or intrinsic factor, leading to selective malabsorption of vitamin B12. Intestinal malabsorption conditions such as celiac disease, gastric resection, and pancreatic disorders can also cause secondary deficiencies.
Other acquired forms are due to chronic exposure to alcohol, chemotherapy, antimetabolites, anticonvulsants, or environmental toxins such as lead, all of which interfere with DNA synthesis or erythroid maturation.
Congenital forms include congenital dyserythropoietic anemias and inherited sideroblastic anemias. Myelodysplastic syndromes are acquired clonal myeloid neoplasms and are not congenital forms.
From a pathogenic standpoint, in nutritional deficiencies, a lack of vitamin B12 or folate impairs DNA synthesis, causing maturation arrest, megaloblastosis, and intramedullary death of erythroid precursors. In sideroblastic anemias, heterogeneous defects in heme synthesis, mitochondrial iron metabolism, or other erythroid processes may lead to iron accumulation in erythroblast mitochondria and formation of ring sideroblasts. In myelodysplastic syndromes, genetic and clonal abnormalities in stem cells generate a population of precursors unable to complete erythroid maturation.
The common pathophysiologic result is persistent ineffective red blood cell production, resulting in hypoproliferative anemia, progressive pallor, fatigue, dyspnea, compensatory tachycardia, and, in vitamin B12 deficiency, neurologic symptoms. In chronic forms, intramedullary death of erythroid precursors and iron accumulation, especially with repeated transfusions or ring sideroblasts, may lead to secondary siderosis with hepatic, cardiac, and endocrine involvement, whereas myelodysplastic syndromes may progress to pancytopenia or acute leukemia.
Risk factors and prevention
The risk factors for the development of anemias due to ineffective erythropoiesis vary by etiology and differ between acquired and congenital forms. In acquired forms, the main determinants are conditions that predispose to vitamin B12 or folate deficiency or exposure to toxic substances; in congenital forms, genetic predisposition is decisive, whereas older age is primarily a risk factor for acquired myelodysplastic syndromes.
For acquired forms, the most relevant risk factors include:
- Inadequate dietary patterns (unsupplemented vegetarian diets, alcohol misuse, chronic undernutrition)
- Gastrointestinal disorders causing malabsorption (celiac disease, gastrectomy, pancreatic insufficiency, Crohn disease)
- Autoimmune gastritis and associated autoimmune diseases; parietal cell antibodies and intrinsic factor antibodies are diagnostic tools for pernicious anemia
- Chronic use of interfering medications (anticonvulsants, chemotherapy agents, methotrexate, hydroxyurea, proton pump inhibitors, or H2 receptor antagonists)
- Exposure to lead or other specifically myelotoxic agents
With regard to prevention, nutritional and iatrogenic forms can be prevented through a balanced diet, vitamin B12 and folate supplementation in at-risk individuals, and monitoring of patients receiving interfering medications.
Other useful measures include:
- Correction of nutritional deficiencies through targeted supplementation in at-risk patients
- Prompt treatment of gastrointestinal disorders causing malabsorption
- Reduction of exposure to toxic substances and prudent use of myelotoxic medications
- Genetic counseling in families with inherited sideroblastic anemia
Clinical manifestations
The clinical manifestations of anemias due to ineffective erythropoiesis result from reduced production of functional red blood cells and the severity of the underlying anemia. The history is characterized by progressive fatigue, often marked pallor of the skin and mucous membranes, exertional dyspnea, compensatory tachycardia and, in chronic forms, easier fatigability and reduced exercise tolerance.
Additional clinical features vary according to etiology:
- Neurologic manifestations such as paresthesias, loss of vibration sense, ataxia, and cognitive impairment primarily suggest vitamin B12 deficiency and are not characteristic of isolated folate deficiency.
- In sideroblastic anemias signs of siderosis (hepatomegaly, cardiomyopathy, skin hyperpigmentation) may occur in transfusion-dependent patients.
- In anemia due to myelodysplastic syndrome symptoms are often insidious and progressive, with refractory anemia and, in advanced forms, neutropenia and thrombocytopenia which increase the risk of infections and bleeding.
- Marked pallor of the skin and mucous membranes
- Possible subclinical jaundice in megaloblastic forms because of mild intramedullary hemolysis
- Absence of lymphadenopathy or splenomegaly in pure forms; splenomegaly may occur in chronic or dysplastic variants
- In vitamin B12 deficiency, objective neurologic signs (reduced reflexes, gait disturbances)
In pediatric patients, some congenital forms may present with growth delay, skeletal abnormalities (in inherited sideroblastic anemias), poor growth and, if untreated, impaired neurocognitive development.
It is important to note that involvement of the other cell lineages may also occur in severe vitamin B12 or folate deficiency; in myelodysplastic syndromes it depends on the subtype and is not limited to advanced stages.
Investigations and diagnosis
The diagnosis of anemias due to ineffective erythropoiesis is based on an integrated, sequential pathway that begins with clinical and laboratory data, with additional morphologic and molecular investigations when indicated. Suspicion arises in the presence of macrocytic anemia or, less commonly, normocytic or microcytic anemia accompanied by reticulocytopenia and absence of signs of peripheral hemolysis.
The first step is complete blood count with red blood cell indices and reticulocyte count, which documents:
- Macrocytic anemia (elevated MCV), or microcytic anemia in sideroblastic variants
- Persistent reticulocytopenia
- The complete blood count may show leukopenia and thrombocytopenia in severe vitamin B12 or folate deficiency and in myelodysplastic syndromes; multiple cytopenias are therefore not exclusive to advanced MDS.
The peripheral blood smear may show macro-ovalocytes, hypersegmented neutrophils, anisopoikilocytosis or, in sideroblastic forms, hypochromic red blood cells and other variable findings; megaloblasts are bone marrow precursors.
The bone marrow aspirate or biopsy are not required in uncomplicated vitamin deficiencies with a typical presentation; they are indicated in unexplained cases, in the presence of cytopenias, or when myelodysplasia or sideroblastic anemia is suspected, and may show:
- Erythroblastic hyperplasia with accumulation of atypical precursors
- Presence of megaloblasts in vitamin deficiencies, ring sideroblasts in sideroblastic forms, morphologic dysplasia in myelodysplastic syndromes
- The other lineages may be preserved or reduced: pancytopenia may occur in severe megaloblastic deficiencies and in various myelodysplastic subtypes
- Measurement of vitamin B12 and folate, with testing for intrinsic factor and gastric parietal cell antibodies for the diagnosis of pernicious anemia
- Measurement of ferritin, serum iron, and transferrin saturation in forms suspected of sideroblastic anemia
- Cytogenetic and molecular studies in cases of myelodysplastic syndrome or suspected clonal disease
Other investigations, including autoimmunity, toxic exposures, and malabsorption, are considered according to the clinical context and results of the initial tests.
The differential diagnosis primarily includes erythroblastopenias, chronic hemolytic anemias, and rare hemoglobinopathies.
Treatment and prognosis
The therapeutic management of anemias due to ineffective erythropoiesis is based on an individualized approach according to etiology, anemia severity, and the patient’s general condition.
In forms due to vitamin B12 deficiency or folate deficiency, treatment consists of correction of the deficiency through oral or parenteral supplementation, with rapid improvement in hematologic findings; neurologic symptoms due to vitamin B12 deficiency may instead resolve slowly and incompletely, especially if treatment is delayed.
In pernicious anemia, vitamin B12 replacement is lifelong; it may be administered parenterally or, in selected adherent patients, as high-dose oral therapy that is effective through passive diffusion.
In sideroblastic anemias, pyridoxine is indicated mainly in ALAS2-related forms and in other potentially responsive variants; it is not a universal therapeutic trial for all forms.
In myelodysplastic syndrome treatment is complex and risk-adapted: in lower-risk forms, transfusion support and erythropoietin are favored, whereas higher-risk forms may require hypomethylating agents, chemotherapy, or bone marrow transplantation.
The long-term monitoring includes assessment of hematologic parameters, management of iron overload, and surveillance for endocrine and cardiac complications, as well as the risk of leukemic progression in myelodysplastic syndromes.
The prognosis depends on the clinical form, timeliness of diagnosis, and response to treatment. Nutritional forms have an excellent prognosis when corrected promptly, whereas congenital or myelodysplastic forms carry a risk of chronic disease, transfusion dependence, iron overload, and possible leukemic progression.
Complications
The complications of anemias due to ineffective erythropoiesis result from persistent anemia, treatment adverse effects, and the underlying disease. The risk of adverse events is greater in patients with chronic disease, children, and older adults.
The main complications include:
- Heart failure secondary to chronic hypoxia, especially in severe and prolonged anemia
- Neurologic impairment (in untreated vitamin B12 deficiency), potentially irreversible
- Systemic siderosis due to iron accumulation, with hepatic, cardiac, or endocrine hemosiderosis, especially in transfusion-dependent patients
- Infections and bleeding in myelodysplastic syndromes with pancytopenia
- Drug-related complications from iron chelators, immunosuppressive agents, or hypomethylating agents
- Progression to pancytopenia or leukemic transformation in advanced myelodysplastic syndromes
Congenital forms may be associated with skeletal abnormalities, growth delay, dysmorphic features, or associated disorders that affect quality of life and life expectancy. In transfusion-dependent patients, management of iron overload is essential.
The quality of life may be impaired by the chronic nature of the disease, the need for frequent treatment and monitoring, and the associated psychological and social burden.
- Cazzola M. Ineffective erythropoiesis and its treatment. Blood. 2022;139(16):2460-2470.
- Green R, Allen LH, Bjørke-Monsen AL, et al. Vitamin B12 deficiency. Nat Rev Dis Primers. 2017;3:17040.
- Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am. 2014;28(4):653-670.
- Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-1228.
- Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006;81(1):104-130.
- Koury MJ, Ponka P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr. 2004;24:105–131.
- Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013;368(2):149–160.
- Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol. 2014;166(4):496–513.
- Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358-1374.
- Fenaux P, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020;382(2):140-151.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.